OptimizeRx CCO Theresa Greco to depart June 15; advisory role through June 2027

OptimizeRx Corp

Greco's separation effective June 15, 2026; she will serve as advisor through June 15, 2027.
She receives 12 months' base salary continuation at $380,000/yr, a $209,000 lump sum bonus target, and COBRA reimbursement for 12 months.
Equity grants continue to vest during the 12-month advisory term; change-of-control special bonus preserved.
Greco subject to 12-month non-compete and non-solicit obligations under Business Protection Agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Theresa Greco

Chief Commercial Officer

OPRX · OptimizeRx Corp

Effective: 2026-06-15
Filed: June 5, 2026, 4:10 PM ET

Accordingly, effective as of the Separation Date, Ms. Greco will no longer serve as the Company’s Chief Commercial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Theresa Greco departed as Chief Commercial Officer at OptimizeRx Corp.

Action: separated
Role: Chief Commercial Officer

Exact text from the filing

Accordingly, effective as of the Separation Date, Ms. Greco will no longer serve as the Company’s Chief Commercial Officer.

View on SEC.gov

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-26-065810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.